SG11201706155XA - Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers - Google Patents
Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersInfo
- Publication number
- SG11201706155XA SG11201706155XA SG11201706155XA SG11201706155XA SG11201706155XA SG 11201706155X A SG11201706155X A SG 11201706155XA SG 11201706155X A SG11201706155X A SG 11201706155XA SG 11201706155X A SG11201706155X A SG 11201706155XA SG 11201706155X A SG11201706155X A SG 11201706155XA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- cancers
- combination
- pancreatic cancer
- immunotherapy against
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134253P | 2015-03-17 | 2015-03-17 | |
| GB201504502A GB201504502D0 (en) | 2015-03-17 | 2015-03-17 | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| PCT/EP2016/055817 WO2016146751A1 (en) | 2015-03-17 | 2016-03-17 | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706155XA true SG11201706155XA (en) | 2017-09-28 |
Family
ID=53016273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706155XA SG11201706155XA (en) | 2015-03-17 | 2016-03-17 | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| SG10202001404VA SG10202001404VA (en) | 2015-03-17 | 2016-03-17 | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202001404VA SG10202001404VA (en) | 2015-03-17 | 2016-03-17 | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10076560B2 (en) |
| EP (1) | EP3270952A1 (en) |
| JP (1) | JP6715856B2 (en) |
| KR (1) | KR20170126929A (en) |
| CN (2) | CN113563456A (en) |
| AR (2) | AR121588A2 (en) |
| AU (4) | AU2016232140B2 (en) |
| BR (1) | BR112017019217A2 (en) |
| CA (1) | CA2979506A1 (en) |
| CR (3) | CR20170419A (en) |
| EA (1) | EA037783B1 (en) |
| GB (1) | GB201504502D0 (en) |
| MA (3) | MA46647A1 (en) |
| MX (1) | MX2017011857A (en) |
| PE (1) | PE20171515A1 (en) |
| SG (2) | SG11201706155XA (en) |
| TW (2) | TWI726872B (en) |
| UA (1) | UA123392C2 (en) |
| WO (1) | WO2016146751A1 (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014110591A1 (en) | 2013-01-14 | 2014-07-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| CA3004830A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| KR20180107102A (en) | 2015-12-16 | 2018-10-01 | 그릿스톤 온콜로지, 인코포레이티드 | Identification of new antigens, manufacture, and uses |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (en) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers |
| DE102016123893A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved binding |
| KR102639592B1 (en) | 2016-12-08 | 2024-02-21 | 이매틱스 바이오테크놀로지스 게엠베하 | T cell receptors with improved pairing |
| CN110167566A (en) * | 2016-12-21 | 2019-08-23 | 弗莱德哈钦森癌症研究中心 | It treats solid tumor cell and escapes the bracket of variant |
| CN111533797A (en) * | 2017-04-10 | 2020-08-14 | 伊玛提克斯生物技术有限公司 | Peptides and peptide compositions thereof for cancer immunotherapy |
| EP3630807A1 (en) | 2017-05-25 | 2020-04-08 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| DE102017115966A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptide molecule with improved dual specificity |
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| CA3078744A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
| CN111630602A (en) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | Reducing presentation of conjugated epitopes by neoantigens |
| DE102017127984B4 (en) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Method for the propagation and activation of γδ T cells |
| KR20200119840A (en) | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T cell production method |
| CA3091414A1 (en) | 2018-02-27 | 2019-09-06 | Leidos, Inc. | Pd-1 peptide inhibitors |
| US20210024603A1 (en) * | 2018-03-16 | 2021-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
| US20210070819A1 (en) * | 2018-03-16 | 2021-03-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| AU2020279371A1 (en) | 2019-05-22 | 2021-12-23 | Leidos, Inc. | LAG 3 binding peptides |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| MX2021015033A (en) | 2019-06-06 | 2022-01-18 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides. |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
| DE102020106710A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
| CN115917010A (en) * | 2020-04-29 | 2023-04-04 | 台北医学大学 | Method for early detection, prediction of treatment response and prognosis of colorectal cancer |
| US11578102B2 (en) | 2020-07-31 | 2023-02-14 | Leidos, Inc. | LAG3 binding peptides |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| EP4225444A1 (en) | 2020-10-12 | 2023-08-16 | Leidos, Inc. | Immunomodulatory peptides |
| CN112557347B (en) * | 2020-11-12 | 2023-10-24 | 渤海大学 | Preparation and detection method of chyle particle migration model in mucus layer |
| CN112462066B (en) * | 2020-12-03 | 2023-05-19 | 中南大学湘雅医院 | Application of FAM3C protein and specific antibody thereof in preparation of nasopharyngeal carcinoma detection kit, kit and application of kit |
| CR20230295A (en) | 2020-12-31 | 2023-07-27 | Immatics Us Inc | CD8 POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE OF THESE |
| CN112760383B (en) * | 2021-03-02 | 2023-07-21 | 上海欧易生物医学科技有限公司 | qRT-PCR internal reference gene applied to lung adenocarcinoma cell subgroup and application thereof |
| CA3217739A1 (en) | 2021-05-05 | 2022-11-10 | Sebastian Bunk | Bma031 antigen binding polypeptides |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| KR102618065B1 (en) * | 2021-12-10 | 2023-12-22 | 성균관대학교산학협력단 | Composition for Diagnosing Pancreatic Cancer and Method for Diagnosing Pancreatic Cancer Using the same |
| CN114214406A (en) * | 2021-12-15 | 2022-03-22 | 天津医科大学总医院 | Triple marker for evaluating immunotherapy reactivity of tumor patients and evaluating tumor prognosis and application thereof |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610031A (en) * | 1993-10-27 | 1997-03-11 | The General Hospital Corporation | B1k chain of laminin and methods of use |
| US6316213B1 (en) * | 1997-03-19 | 2001-11-13 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian, breast and lung cancer |
| AU4158799A (en) * | 1998-06-06 | 1999-12-30 | Genostic Pharma Limited | Probes used for genetic filing |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| CN1469926A (en) * | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | Compositions and methods for the therapy and diagnosis of lung cancer |
| WO2003010327A2 (en) * | 2001-02-21 | 2003-02-06 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
| US20030021796A1 (en) * | 2001-05-04 | 2003-01-30 | Leszek Ignatowicz | Method of enhancing T cell immunity by selection of antigen specific T cells |
| JP2003321494A (en) * | 2002-02-26 | 2003-11-11 | Daiichi Fine Chemical Co Ltd | Method for adjusting activation of prommp-7 |
| AU2003274463B2 (en) * | 2002-06-10 | 2009-10-29 | University Of Rochester | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2003298014A1 (en) * | 2002-12-04 | 2004-06-23 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| DK1760089T3 (en) * | 2005-09-05 | 2009-11-16 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| GB0611116D0 (en) * | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
| WO2009015842A2 (en) * | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| EP2127664A1 (en) * | 2008-02-15 | 2009-12-02 | Max-Delbrück-Centrum | Change of the load state of MHC molecules by dipeptides |
| CA2718830C (en) * | 2008-03-31 | 2017-04-18 | Kyoto University | Method for proliferation of pluripotent stem cells |
| SI2119726T2 (en) * | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| US8568996B2 (en) * | 2008-10-21 | 2013-10-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | MMP activation peptide detection in biological samples |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US10706955B2 (en) * | 2010-03-23 | 2020-07-07 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| AU2012203810B2 (en) * | 2011-06-22 | 2013-12-05 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
| WO2013033609A2 (en) * | 2011-08-31 | 2013-03-07 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
| EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| US20140065620A1 (en) * | 2011-12-29 | 2014-03-06 | Mayo Foundation For Medical Education And Research | Nucleic acids for detecting breast cancer |
| TWI777194B (en) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same |
| CN104163862B (en) * | 2013-12-04 | 2017-02-08 | 魏敏杰 | GRP78 peptide epitopes combined with human MHC-I (Major Histocompatibility Complex-I) molecule |
| CN104306976A (en) * | 2014-04-26 | 2015-01-28 | 深圳市康尔诺生物技术有限公司 | Efficient individual tumor immunotherapy and application thereof |
-
2015
- 2015-03-17 GB GB201504502A patent/GB201504502D0/en not_active Ceased
-
2016
- 2016-03-17 AU AU2016232140A patent/AU2016232140B2/en active Active
- 2016-03-17 WO PCT/EP2016/055817 patent/WO2016146751A1/en active Application Filing
- 2016-03-17 JP JP2017547530A patent/JP6715856B2/en active Active
- 2016-03-17 MA MA46647A patent/MA46647A1/en unknown
- 2016-03-17 EA EA201791853A patent/EA037783B1/en unknown
- 2016-03-17 SG SG11201706155XA patent/SG11201706155XA/en unknown
- 2016-03-17 CN CN202110838669.8A patent/CN113563456A/en active Pending
- 2016-03-17 TW TW105108310A patent/TWI726872B/en active
- 2016-03-17 US US15/073,528 patent/US10076560B2/en active Active
- 2016-03-17 TW TW109140068A patent/TWI769586B/en active
- 2016-03-17 KR KR1020177025935A patent/KR20170126929A/en not_active Application Discontinuation
- 2016-03-17 EP EP16710223.5A patent/EP3270952A1/en active Pending
- 2016-03-17 CN CN201680015234.0A patent/CN107428810B/en active Active
- 2016-03-17 CA CA2979506A patent/CA2979506A1/en active Pending
- 2016-03-17 BR BR112017019217-9A patent/BR112017019217A2/en active Search and Examination
- 2016-03-17 MA MA46648A patent/MA46648B2/en unknown
- 2016-03-17 CR CR20170419A patent/CR20170419A/en unknown
- 2016-03-17 PE PE2017001485A patent/PE20171515A1/en unknown
- 2016-03-17 CR CR20210234A patent/CR20210234A/en unknown
- 2016-03-17 MX MX2017011857A patent/MX2017011857A/en unknown
- 2016-03-17 CR CR20210233A patent/CR20210233A/en unknown
- 2016-03-17 UA UAA201707771A patent/UA123392C2/en unknown
- 2016-03-17 SG SG10202001404VA patent/SG10202001404VA/en unknown
- 2016-03-17 MA MA40713A patent/MA40713A1/en unknown
-
2018
- 2018-01-12 US US15/869,471 patent/US10357551B2/en active Active
-
2020
- 2020-08-18 AU AU2020220070A patent/AU2020220070B2/en active Active
- 2020-08-18 AU AU2020220072A patent/AU2020220072B2/en active Active
- 2020-08-18 AU AU2020220073A patent/AU2020220073B2/en active Active
-
2021
- 2021-02-24 AR ARP210100473A patent/AR121588A2/en unknown
- 2021-02-24 AR ARP210100472A patent/AR121587A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210709T8 (en) | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | |
| SG10202001404VA (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | |
| HK1252868A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| SG10202101368WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| SG10202001665QA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| IL258599A (en) | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| GB201511792D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers | |
| HUE054453T2 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| IL256160A (en) | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | |
| HK1255542A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | |
| IL280879A (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | |
| HK1255541A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers |